Targeted Polymeric Nanoparticles Loaded With Cetuximab and Decorated With Somatostatin Analogue to Colon Cancer
NCT ID: NCT03774680
Last Updated: 2019-10-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
30 participants
INTERVENTIONAL
2020-02-01
2021-01-11
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Phase II Study of the Safety and Efficacy of E7820 Plus Cetuximab in Colorectal Cancer, Preceded by a Run-in Study in Advanced Solid Tumors
NCT00309179
A Study of Nanrilkefusp Alfa (SOT101) in Combination With Cetuximab to Evaluate the Efficacy and Safety in Patients With Colorectal Cancer
NCT05619172
A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)
NCT03833700
AZD6244 With Cetuximab for Solid Tumors and Colorectal Cancer
NCT01287130
BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer
NCT00326495
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cetuximab nanoparticles goup
A group of volunteers infected colon cancer or colorectal cancer received cetuximab in the formulated nanoparticles
Cetuximab nanoparticles
The active group will receive cetuximab in nanoparticles as an anti-microbial drug.
Oral approved anticancer drug
A group of volunteers infected with colon cancer or colorectal cancer received placebo anticancer drug.
Oral approved anticancer drug
The placebo group will receive topical FDA approved anti-microbial jel in different dosage forms as control drug.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cetuximab nanoparticles
The active group will receive cetuximab in nanoparticles as an anti-microbial drug.
Oral approved anticancer drug
The placebo group will receive topical FDA approved anti-microbial jel in different dosage forms as control drug.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Follow up and collect data for a local and systemic activity of cetuximab
* The systemic oral capsule of cetuximab be also given to enhance the activity as an anti-cancer activities
Exclusion Criteria
* Stomach disease
* Colon cancer
20 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ahmed A. H. Abdellatif
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ahmed A. H. Abdellatif
Assistant Professor of Pharmaceutics, Faculty of Pharmacy
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Assiut Clinic
Asyut, , Egypt
Buraidah Clinic
Buraidah, Al Qassim, Saudi Arabia
Faculty of Pharmacy
Buraidah, Al-Qassim Region, Saudi Arabia
Pharmaceutics dept., Faculty of Pharmacy, Qassim University
Buraidah, Al-Qassim Region, Saudi Arabia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Hafez Abdellatif AA, Abdelhafez WA, Sarhan HA. Somatostatin Decorated Quantum Dots for Targeting of Somatostatin Receptors. Iran J Pharm Res. 2018 Spring;17(2):513-524.
Abdellatif AA, Zayed G, El-Bakry A, Zaky A, Saleem IY, Tawfeek HM. Novel gold nanoparticles coated with somatostatin as a potential delivery system for targeting somatostatin receptors. Drug Dev Ind Pharm. 2016 Nov;42(11):1782-91. doi: 10.3109/03639045.2016.1173052. Epub 2016 May 5.
Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS, Bannon F, Ahn JV, Johnson CJ, Bonaventure A, Marcos-Gragera R, Stiller C, Azevedo e Silva G, Chen WQ, Ogunbiyi OJ, Rachet B, Soeberg MJ, You H, Matsuda T, Bielska-Lasota M, Storm H, Tucker TC, Coleman MP; CONCORD Working Group. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet. 2015 Mar 14;385(9972):977-1010. doi: 10.1016/S0140-6736(14)62038-9. Epub 2014 Nov 26.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AlAzharCetuximab
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.